Patents

Prolight has a strong patent portfolio

- The patent situation for the digital immunoassay, Psyros™

Prolight currently have six families of patent applications relating to the Psyros™ technology. The first three are currently in the national / regional phases in a range of territories worldwide. Families four and five are in the PCT phase and will enter the national / regional phases later this year. The sixth is a priority application in the UK.
 
In February 2025 the company received two Notice of Intention to Grant for core Psyros patent and an extension to the core application from the European Patent Office (EPO), protecting their single molecule counting POC technology. A number of formalities will now take place before the process is complete and the patents are fully granted by the EPO.

- The patent situation for MicroFlex

For MicroFlex, the patent portfolio consists of five registered patents (two in the US, two in the EU, and one in Sweden) and three patent applications that have advanced to the national phase and are now being pursued in various territories.

 

One of the patent applications pertains to how the sampling tube can be directly integrated into the test card. This enables a very simple workflow for all types of clinical environments. No specially trained personnel are needed to pipette and centrifuge the blood sample. MicroFlex thus creates the conditions to offer a fully automated platform for immunodiagnostics.

 

The most recently approved patent (October 2024) concerns a European patent based on a groundbreaking solution for separating plasma from whole blood in a liquid-based consumable. The separation produces high-quality plasma, requires minimal physical space, and is performed in a short amount of time, unlocking new potential business opportunities by integrating the technology into other liquid-based disposable systems.

Subscribe